Search
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEtranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigationalHemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX. … The therapy involves a one-time infusion of a viral vector carrying a codon-optimized DNA sequence of the gain-of-function Padua variant of human Factor IX controlled by a liver-specific promotor 1.
Factor IX Complex (Human)
go.drugbank.com/drugs/DB11330ApprovedInvestigationalexperiencing acute major bleeding or requiring rapid reversal of therapy. … Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma.
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune … Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.
Bromelains
go.drugbank.com/drugs/DB13281ApprovedInvestigationalBromelain is a protease enzyme derived from the stems of pineapples that is composed of a mixture of different thiol endopeptidases and other components like phosphatase, glucosidase, peroxidase, cellulase … Bromelain holds potential therapeutic effect as a treatment of conditions including angina pectoris, bronchitis, sinusitis, surgical trauma, and osteoarthritis.
Categories: Preparations for Treatment of Wounds and UlcersProducts: Bromelain Pineapple Enzyme 50 Mg Nu LifeLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.
Products: TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tabletsMethyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigationalMethyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.
International brands: Nu-MedopaProducts: Nu-medopa Tab 250mg, Nu-medopa Tab 500mgPheneticillin
go.drugbank.com/drugs/DB13337ApprovedPheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.
Categories: combinations of penicillinsPolysorbate 80
go.drugbank.com/drugs/DB11063ApprovedInvestigationalPolysorbate 80 is an excipient that is used to stabilize aqueous formulations of medications for parenteral administration or vaccinations. … In food or pharmaceutical products, it can act as an emulsifier.
Categories: Compounds used in a research, industrial, or household setting